This study found that, over time, treatment with sunitinib resulted in an increasing prevalence of hypogonadism among male patients diagnosed with metastatic renal cell carcinoma. However, administering testosterone replacement therapy led to clinically significant improvements in quality of life. Metastatic renal cell carcinoma (mRCC) is a challenging disease to treat, and single-agent tyrosine kinase inhibitors...